Skip to main content
. 2022 May 10;20:138–146. doi: 10.1016/j.reth.2022.04.005

Fig. 5.

Fig. 5

TRIM14 was a direct target of miR-186-5p. (A) The interacted sites between miR-186-5p and TRIM14 3′UTR were predicted by starBase. (B and C) The binding relationship between miR-186-5p and TRIM14 were validated by dual-luciferase reporter assay and RNA-pull down assay. (D) The interference efficiency of anti-miR-186-5p and overexpression efficiency of miR-186-5p were tested by RT-qPCR. (E and F) TRIM14 mRNA and protein expression were analyzed by RT-qPCR and western blot assay in CMECs transfected with miR-NC, miR-186-5p, anti-miR-NC, or anti-miR-186-5p. (G) TRIM14 mRNA expression was tested by RT-qPCR in serum samples of CAD patients and healthy controls. (H and I) The correlation between TRIM14 and miR-186-5p or circ_ROBO2 was analyzed in CAD patient serum. (J and K) The mRNA and protein levels of TRIM14 were detected by RT-qPCR and western blot assay in CMECs treated with or without ox-LDL. (L and M) TRIM14 mRNA and protein levels were assessed by RT-qPCR and western blot assay in CMECs transfected with sh-NC, sh-circ_ROBO2, sh-circ_ROBO2 + anti-miR-NC, or sh-circ_ROBO2 + anti-miR-186-5p. ∗P < 0.05.